MHMareyah Alshaikh Husain

Mareyah Alshaikh Husain

*This is an algorithmically generated author record based on publicly available information.

Mareyah Alshaikh Husain has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Synchronizing Beats: From Theory to Advances and Insight in Cardiac Resynchronization Therapy

    by Abdulmohsen Almusaad, Muneera AlTaweel, Abdulrahman Abdullatif Alarfaj, Abdullah Dhawi Al-Otaibi, Mareyah Alshaikh Husain, Rasmah Saad Alharajin, Zainab Albahrani, Yousef Alanazi, Faisal Rabeea Alananzi, Sarah AlMukhaylid, et al.

    Cardiac resynchronization therapy (CRT) is an established treatment for select patients with systolic heart failure, left ventricular conduction delay, and dyssynchronous contraction. Landmark trials have shown CRT’s benefits on symptoms, exercise capacity, reverse remodeling, hospitalization rates, and mortality. However, limitations exist including sub-optimal patient selection, procedural complexity, high non-responder rates, and device-related adverse effects. This review summarizes the evolution, physiology, clinical trial evidence, patient selection, delivery, and optimization of CRT. Key areas covered include guidelines for CRT use, invasive and noninvasive imaging to improve outcomes, alternative pacing sites to enhance response, and advances in lead technology and implantation techniques. Gaps in current knowledge are highlighted along with future directions for research to refine CRT utilization and improve real-world clinical outcomes. With further studies to address remaining questions, CRT is poised to become an even more effective therapy for heart failure patients with dyssynchronous cardiomyopathy.

  • Open Access

    An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies

    by Muneera Altaweel, Abdulmohsen AlMusaad, Gousay Alkhazmari, Hussain Alrowaily, Maram AlSubaiee, Mareyah Alshaikh Husain, Nouf Alomayrin, Rafyel Al Muaiweed, Norah Aleid, Abdulrahman A Alarfaj, et al.

    Background: COVID-19 was initially identified as a respiratory system disorder, but it has been discovered to interact with and influence the cardiovascular system. COVID-19-associated cardiovascular (CV) complications are common, resulting in high acute phase mortality and a large number of morbidities in the chronic phase, thus severely impacting patients' quality of life and health outcomes. Nevertheless, clinical, cellular, and molecular biological factors underlying the pathophysiology of cardiovascular complications associated with COVID-19 are poorly understood. Objective: This review investigates putative underlying clinical factors as well as cellular and molecular biological mechanisms by which COVID-19 leads to acute CV complications, including state-of-the-art genomic sequencing-based findings, assessing the long-term CV consequences of COVID-19, and aiming to shed light on developing strategies for differential diagnosis, risk prognostic stratification, prevention, and clinical management of CV sequlea in COVID-19 patients. Methods: For this purpose, a through review of literature and published data was carried out from first report of COVID-19 till October 2023 to find out a comprehensive account of clinical, cellular and molecular genetic factors underlying COVID-19-associated cardiovascular diseases. Results: We found that the relationship between COVID-19 and CV risk is complex and multifaceted. In addition to acute COVID-19 detertriuos effects, COVID-19 survivors may experience long-term CV effects. We provide a detailed account of the involvement of a large number of genomic alterations, microRNAs, and novel viral as well as host proteins in CVDs associated with COVID-19, which has helped identify some novel drug targets to treat COVID-19-related cardiovascular complications. Conclusions: The relationship between COVID-19 and CV risk is complex and multifaceted. While COVID-19 primarily affects the respiratory system, it can also significantly affect CV health. as compared to classical cardiovascular diseases, there are new clinical, cellular and molecular biological factors in CVDs related to COVID-19, that need specific diagnostic assays, prognostic stratification and treatment modules. Therefore, specail care is must taken to treat cardiovascular diseases associated with COVID-19.